This was when he revealed Pfizer’s ongoing attempts at developing a solution - a vaccine that could potentially provide protection against COVID-19 year-round. And therefore, people need a solution that would last them all year. And despite its waning effectiveness like every other vaccine, the brand has held its own in offering protection against severe disease, hospitalisation and death.īourla suggested that people might develop 'vaccine fatigue' and that fewer individuals would opt for a fourth dose than the third booster shot.
The Pfizer-BioNTech vaccine wasn’t just one of the first COVID-19 vaccines to hit the market, but it has also proven to be one of the most effective. He said that while it’s easy to take action against a single variant, they are taking up a bigger challenge to develop a vaccine that can be far more effective "so you don't have two different vaccines for different variants". On Wednesday, April 13, the pharma giant's CEO Albert Bourla spoke of the new vaccine against the Omicron strain and older variants of COVID-19 at the International Federation of Pharmaceutical Manufacturers and Associations' press conference. And what the world ideally needs at a time like this is a vaccine that can battle all of these variants. For instance, the new XE and BA.2 coronavirus have caused a lot of uncertainty and worry, as people struggle to grapple with their spread. New variants of the COVID-19-causing virus have been emerging at an alarming rate. The ever-ambitious Pfizer has declared its intentions to develop a COVID-19 vaccine that would be effective against all known novel coronavirus variants by the end of 2022.
0 kommentar(er)
